Vilanterol is an ultra-long-acting β2-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).

[1][2] The combination is also approved for the treatment of asthma in Canada, Europe, Japan[3] and New Zealand.

[4] Vilanterol is available in following combinations:

This drug article relating to the respiratory system is a stub.

You can help Wikipedia by expanding it.